{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:28:31Z","timestamp":1792794511464,"version":"4.5.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute for Health Research\/Biomedical Research Center at Great Ormond Street Hospital for Children","id":[{"id":"https:\/\/ror.org\/00zn2c847","id-type":"ROR","asserted-by":"crossref"}]},{"name":"NHS Foundation Trust"},{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pediatric low-grade glioma (pLGG) is the most common childhood brain tumor group. The natural history, when curative resection is not possible, is one of a chronic disease with periods of tumor stability and episodes of tumor progression. While there is a high overall survival rate, many patients experience significant and potentially lifelong morbidities. The majority of pLGGs have an underlying activation of the RAS\/MAPK pathway due to mutational events, leading to the use of molecularly targeted therapies in clinical trials, with recent regulatory approval for the combination of BRAF and MEK inhibition for BRAFV600E mutated pLGG. Despite encouraging activity, tumor regrowth can occur during therapy due to drug resistance, off treatment as tumor recurrence, or as reported in some patients as a rapid rebound growth within 3 months of discontinuing targeted therapy. Definitions of these patterns of regrowth have not been well described in pLGG. For this reason, the International Pediatric Low-Grade Glioma Coalition, a global group of physicians and scientists, formed the Resistance, Rebound, and Recurrence (R3) working group to study resistance, rebound, and recurrence. A modified Delphi approach was undertaken to produce consensus-based definitions and recommendations for regrowth patterns in pLGG with specific reference to targeted therapies.<\/jats:p>","DOI":"10.1093\/neuonc\/noae074","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T19:30:10Z","timestamp":1713295810000},"page":"1357-1366","source":"Crossref","is-referenced-by-count":30,"title":["Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions\u2014International Pediatric Low-Grade Glioma Coalition"],"prefix":"10.1093","volume":"26","author":[{"given":"Patricia","family":"O\u2019Hare","sequence":"first","affiliation":[{"name":"Department of Paediatric Oncology, Royal Belfast Hospital for Sick Children , Northern Ireland , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabitha","family":"Cooney","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center , Boston, Massachusetts ,\u00a0 USA"},{"name":"Department of Pediatrics, Harvard Medical School, Broad Institute , Cambridge, Massachusetts ,\u00a0 USA"},{"name":"Day One Biopharmaceuticals , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"de Blank","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center , Boston, Massachusetts ,\u00a0 USA"},{"name":"Department of Pediatrics, Harvard Medical School, Broad Institute , Cambridge, Massachusetts ,\u00a0 USA"},{"name":"University of Cincinnati College of Medicine and Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H","family":"Gutmann","sequence":"additional","affiliation":[{"name":"Department of Neurology, Washington University School of Medicine , St. Louis, Missouri , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kieran","sequence":"additional","affiliation":[{"name":"Day One Biopharmaceuticals , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Milde","sequence":"additional","affiliation":[{"name":"Clinical Pediatric Oncology,\u00a0Hopp Children\u2019s Cancer Center (KiTZ) , Heidelberg , Germany"},{"name":"Heidelberg University Hospital, Heidelberg , Germany"},{"name":"German Cancer Research Center, National Center for Tumor Diseases (NCT) , Heidelberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Fangusaro","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta and Emory University School of Medicine , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fisher","sequence":"additional","affiliation":[{"name":"Division of Oncology, The Children\u2019s Hospital of Philadelphia , Philadelphia, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivaram","family":"Avula","sequence":"additional","affiliation":[{"name":"Department of Radiology, Alder Hey Children\u2019s NHS Foundation Trust , Liverpool , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Packer","sequence":"additional","affiliation":[{"name":"Brain Tumor Institute, Center for Neuroscience and Behavioral Medicine, Children\u2019s National Hospital , Washington, District of Columbia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2568-0877","authenticated-orcid":false,"given":"Kohei","family":"Fukuoka","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Saitama Children\u2019s Medical Center , Saitama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kshitij","family":"Mankad","sequence":"additional","affiliation":[{"name":"Department of Radiology, Great Ormond Street Hospital for Children NHS Foundation Trust, Department of Radiology , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Mueller","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neurosurgery and Pediatrics, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela J","family":"Waanders","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Northwestern University Feinberg School of Medicine , Chicago, Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Opocher","sequence":"additional","affiliation":[{"name":"Paediatric Haematology, Oncology and Stem Cell Transplant Division, Padua University Hospital , Padua , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6832-6539","authenticated-orcid":false,"given":"Eric","family":"Bouffet","sequence":"additional","affiliation":[{"name":"The Hospital for Sick Children and Department of Paediatrics, University of Toronto , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Raabe","sequence":"additional","affiliation":[{"name":"Division of Pediatric Oncology, Department of Oncology, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"},{"name":"Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha Entz","family":"Werle","sequence":"additional","affiliation":[{"name":"Pediatric Onco-Hematology Department, University Hospital of Strasbourg. UMR CNRS 7021, University of Strasbourg , Strasbourg ,\u00a0 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amedeo A","family":"Azizi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine and Comprehensive Centre of Pediatrics, Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan J","family":"Robison","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology, Children\u2019s Hospital Los Angeles, University of Southern California Keck School of Medicine , Los Angeles, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Hern\u00e1iz Driever","sequence":"additional","affiliation":[{"name":"Charit\u00e9-Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, German HIT-LOGGIC-Registry for LGG in children and adolescents, Department of Pediatric Oncology\/Hematology , Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Russo","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover , New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Netteke","family":"Schouten","sequence":"additional","affiliation":[{"name":"Princess Maxima Center for Pediatric Oncology , Utrecht , Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis M","family":"van Tilburg","sequence":"additional","affiliation":[{"name":"Clinical Pediatric Oncology,\u00a0Hopp Children\u2019s Cancer Center (KiTZ) , Heidelberg , Germany"},{"name":"Heidelberg University Hospital, Heidelberg , Germany"},{"name":"German Cancer Research Center, National Center for Tumor Diseases (NCT) , Heidelberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Sehested","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine, The University Hospital Rigshospitalet , Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4773-3001","authenticated-orcid":false,"given":"Jacques","family":"Grill","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescent Oncology , Villejuif , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratiti","family":"Bandopadhayay","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center , Boston, Massachusetts ,\u00a0 USA"},{"name":"Department of Pediatrics, Harvard Medical School, Broad Institute , Cambridge, Massachusetts ,\u00a0 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-215X","authenticated-orcid":false,"given":"John-Paul","family":"Kilday","sequence":"additional","affiliation":[{"name":"The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, University of Manchester, and Royal Manchester Children\u2019s Hospital , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Witt","sequence":"additional","affiliation":[{"name":"Clinical Pediatric Oncology,\u00a0Hopp Children\u2019s Cancer Center (KiTZ) , Heidelberg , Germany"},{"name":"Heidelberg University Hospital, Heidelberg , Germany"},{"name":"German Cancer Research Center, National Center for Tumor Diseases (NCT) , Heidelberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Ashley","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center. Pediatric Neuro-Oncology, Preuss Laboratory for Brain Tumor Research, Durham , North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit Betina","family":"Ertl-Wagner","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, The Hospital for Sick Children , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5019-2683","authenticated-orcid":false,"given":"Uri","family":"Tabori","sequence":"additional","affiliation":[{"name":"The Hospital for Sick Children and Department of Paediatrics, University of Toronto , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8219-9807","authenticated-orcid":false,"given":"Darren R","family":"Hargrave","sequence":"additional","affiliation":[{"name":"UCL Great Ormond Street Institute of Child Health, Great Ormond Street Hospital for Children , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"issue":"7","key":"2024080523460533400_CIT0001","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/pbc.24958","article-title":"Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: An analysis of the Surveillance Epidemiology and End Results (SEER) database","volume":"61","author":"Bandopadhayay","year":"2014","journal-title":"Pediatr Blood Cancer."},{"issue":"2","key":"2024080523460533400_CIT0002","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/neuonc\/nox141","article-title":"Pediatric low-grade gliomas: Next biologically driven steps","volume":"20","author":"Jones","year":"2018","journal-title":"Neuro Oncol"},{"key":"2024080523460533400_CIT0003","doi-asserted-by":"crossref","first-page":"100857","DOI":"10.1016\/j.neo.2022.100857","article-title":"Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era","volume":"36","author":"Manoharan","year":"2023","journal-title":"Neoplasia"},{"key":"2024080523460533400_CIT0004","doi-asserted-by":"crossref","first-page":"LBA2002","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA2002","article-title":"Primary analysis of a phase II trial of dabrafenib plus trametinib (dab + tram) in BRAF V600\u2013mutant pediatric low-grade glioma (pLGG)","volume":"40","author":"Bouffet","year":"2022","journal-title":"J Clin Oncol."},{"key":"2024080523460533400_CIT0005","author":"Administration UFaD","year":"2023"},{"issue":"24","key":"2024080523460533400_CIT0006","doi-asserted-by":"crossref","first-page":"7303","DOI":"10.1158\/1078-0432.CCR-19-2177","article-title":"Efficacy and safety of Dabrafenib in pediatric patients with BRAF V600 mutation-positive relapsed or refractory low-grade glioma: Results from a Phase I\/IIa Study","volume":"25","author":"Hargrave","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2024080523460533400_CIT0007","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1200\/JCO.22.01000","article-title":"Efficacy and safety of Trametinib monotherapy or in combination with Dabrafenib in pediatric BRAF V600-mutant low-grade glioma","volume":"41","author":"Bouffet","year":"2023","journal-title":"J Clin Oncol."},{"issue":"10","key":"2024080523460533400_CIT0008","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/neuonc\/noab047","article-title":"A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: A Pediatric Brain Tumor Consortium study","volume":"23","author":"Fangusaro","year":"2021","journal-title":"Neuro Oncol"},{"issue":"7","key":"2024080523460533400_CIT0009","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: A multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol."},{"issue":"21","key":"2024080523460533400_CIT0010","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.18632\/oncotarget.27600","article-title":"Phase I study of vemurafenib in children with recurrent or progressive BRAF(V600E) mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002)","volume":"11","author":"Nicolaides","year":"2020","journal-title":"Oncotarget"},{"key":"2024080523460533400_CIT0011","doi-asserted-by":"crossref","first-page":"10004","DOI":"10.1200\/JCO.2023.41.16_suppl.10004","article-title":"Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study","volume":"41","author":"Khuong-Quang","year":"2023","journal-title":"J Clin Oncol."},{"issue":"May","key":"2024080523460533400_CIT0012","first-page":"PO.19.00298","article-title":"Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition","volume":"4","author":"Nobre","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"2024080523460533400_CIT0013","doi-asserted-by":"crossref","first-page":"1074726","DOI":"10.3389\/fonc.2022.1074726","article-title":"Response and resistance to BRAF(V600E) inhibition in gliomas: Roadblocks ahead","volume":"12","author":"Capogiri","year":"2022","journal-title":"Front Oncol."},{"issue":"25","key":"2024080523460533400_CIT0014","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1200\/JCO.2016.71.8726","article-title":"Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas","volume":"35","author":"Lassaletta","year":"2017","journal-title":"J Clin Oncol."},{"issue":"1","key":"2024080523460533400_CIT0015","first-page":"vdac182","article-title":"Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment","volume":"5","author":"Tsai","year":"2023","journal-title":"Neurooncol Adv."},{"key":"2024080523460533400_CIT0016","doi-asserted-by":"crossref","first-page":"i91","DOI":"10.1093\/neuonc\/noac079.332","article-title":"LGG-17. Preventing recurrence: Targeting molecular mechanisms driving tumor growth rebound after MAPKi withdrawal in pediatric low-grade glioma","volume":"24","author":"Kocher","year":"2022","journal-title":"Neuro-Oncology."},{"issue":"6","key":"2024080523460533400_CIT0017","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/S1470-2045(20)30064-4","article-title":"Response assessment in paediatric low-grade glioma: Recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group","volume":"21","author":"Fangusaro","year":"2020","journal-title":"Lancet Oncol."},{"issue":"3","key":"2024080523460533400_CIT0018","first-page":"458","article-title":"An experimental application of the DELPHI method to the use of experts","volume":"9","author":"Norman Dalkey","year":"1963","journal-title":"Experts Management Sci"},{"issue":"4","key":"2024080523460533400_CIT0019","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","article-title":"Research guidelines for the Delphi survey technique","volume":"32","author":"Hasson","year":"2000","journal-title":"J Adv Nurs."},{"issue":"8","key":"2024080523460533400_CIT0020","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1177\/0269216317690685","article-title":"Guidance on Conducting and REporting DElphi Studies (CREDES) in palliative care: Recommendations based on a methodological systematic review","volume":"31","author":"Junger","year":"2017","journal-title":"Palliat Med."},{"issue":"10","key":"2024080523460533400_CIT0021","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S1470-2045(10)70222-9","article-title":"Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: An open-label multicentre randomised phase 3 trial","volume":"11","author":"Le Cesne","year":"2010","journal-title":"Lancet Oncol."},{"issue":"14","key":"2024080523460533400_CIT0022","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1158\/1078-0432.CCR-12-0002","article-title":"Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients","volume":"18","author":"Griffioen","year":"2012","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2024080523460533400_CIT0023","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.eururo.2014.10.034","article-title":"Evidence and clinical relevance of tumor flare in patients who discontinue tyrosine kinase inhibitors for treatment of metastatic renal cell carcinoma","volume":"68","author":"Iacovelli","year":"2015","journal-title":"Eur Urol."},{"issue":"1","key":"2024080523460533400_CIT0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm12010325","article-title":"The outcome of discontinuing tyrosine kinase inhibitors in advanced sarcoma following a favorable tumor response to antiangiogenics therapy","volume":"12","author":"Zhang","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"2024080523460533400_CIT0025","doi-asserted-by":"crossref","first-page":"100367","DOI":"10.1016\/j.ctarc.2021.100367","article-title":"Tumor flare of brain metastases upon dose interruption of sunitinib in a patient with metastatic renal cell carcinoma","volume":"27","author":"Amirault","year":"2021","journal-title":"Cancer Treat Res Commun"},{"issue":"19","key":"2024080523460533400_CIT0026","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1158\/1078-0432.CCR-11-1468","article-title":"Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: Implications for clinical trial design","volume":"17","author":"Chaft","year":"2011","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2024080523460533400_CIT0027","first-page":"1","article-title":"Rapid pleural effusion after discontinuation of lenvatinib in a patient with pleural metastasis from thyroid cancer","volume":"2019","author":"Uchida","year":"2019","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"11","key":"2024080523460533400_CIT0028","doi-asserted-by":"crossref","first-page":"e19408","DOI":"10.1097\/MD.0000000000019408","article-title":"Rapid disease progression after discontinuation of lenvatinib in thyroid cancer","volume":"99","author":"Yamazaki","year":"2020","journal-title":"Medicine (Baltim)."},{"issue":"3","key":"2024080523460533400_CIT0029","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3803\/EnM.2014.29.3.388","article-title":"Accelerated disease progression after discontinuation of sorafenib in a patient with metastatic papillary thyroid cancer","volume":"29","author":"Yun","year":"2014","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"7","key":"2024080523460533400_CIT0030","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with Dabrafenib plus Trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med."},{"issue":"Jan","key":"2024080523460533400_CIT0031","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2022.11.009","article-title":"BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes","volume":"179","author":"Lee","year":"2023","journal-title":"Eur J Cancer."},{"issue":"5","key":"2024080523460533400_CIT0032","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1080\/15384047.2015.1026507","article-title":"Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy","volume":"16","author":"Wyluda","year":"2015","journal-title":"Cancer Biol Ther."},{"issue":"4","key":"2024080523460533400_CIT0033","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1111\/bjd.15345","article-title":"BRAF V600 inhibitor discontinuation after complete response in advanced melanoma: A retrospective analysis of 16 patients","volume":"177","author":"Vanhaecke","year":"2017","journal-title":"Br J Dermatol."},{"issue":"1","key":"2024080523460533400_CIT0034","doi-asserted-by":"crossref","first-page":"18878","DOI":"10.1038\/s41598-020-75837-5","article-title":"Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma","volume":"10","author":"Warburton","year":"2020","journal-title":"Sci Rep."},{"issue":"4","key":"2024080523460533400_CIT0035","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/CMR.0000000000000169","article-title":"Complete remission of metastatic melanoma upon BRAF inhibitor treatment - what happens after discontinuation","volume":"25","author":"Tolk","year":"2015","journal-title":"Melanoma Res."},{"issue":"10","key":"2024080523460533400_CIT0036","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.3390\/cancers13102312","article-title":"Discontinuation of BRAF\/MEK-directed targeted therapy after complete remission of metastatic melanoma-a retrospective multicenter ADOReg Study","volume":"13","author":"Stege","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"2024080523460533400_CIT0037","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/bjc.2016.321","article-title":"Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: A case series","volume":"115","author":"Carlino","year":"2016","journal-title":"Br J Cancer."},{"issue":"May","key":"2024080523460533400_CIT0038","first-page":"6660571","article-title":"Prognostic value of ctDNA mutation in melanoma: A meta-analysis","volume":"2021","author":"Zheng","year":"2021","journal-title":"J Oncol"},{"issue":"3","key":"2024080523460533400_CIT0039","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(20)30726-9","article-title":"Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: A clinical validation study","volume":"22","author":"Syeda","year":"2021","journal-title":"Lancet Oncol."},{"issue":"2","key":"2024080523460533400_CIT0040","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2213329","article-title":"BRAF-MEK inhibition in newly diagnosed papillary craniopharyngiomas","volume":"389","author":"Brastianos","year":"2023","journal-title":"N Engl J Med."},{"issue":"11","key":"2024080523460533400_CIT0041","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.3390\/cancers14112683","article-title":"The clinical applications of liquid biopsies in pediatric brain tumors: A systematic literature review","volume":"14","author":"Greuter","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"Feb","key":"2024080523460533400_CIT0042","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fcell.2020.00045","article-title":"Beyond the blood: CSF-derived cfDNA for diagnosis and characterization of CNS tumors","volume":"8","author":"McEwen","year":"2020","journal-title":"Front Cell Dev Biol."},{"issue":"7","key":"2024080523460533400_CIT0043","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11912-021-01065-3","article-title":"Treatment following progression in metastatic melanoma: The State of the Art from Scientific Literature to Clinical Need","volume":"23","author":"Serra","year":"2021","journal-title":"Curr Oncol Rep."},{"issue":"20","key":"2024080523460533400_CIT0044","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/djs353","article-title":"When progressive disease does not mean treatment failure: Reconsidering the criteria for progression","volume":"104","author":"Oxnard","year":"2012","journal-title":"J Natl Cancer Inst."},{"issue":"15","key":"2024080523460533400_CIT0045","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","article-title":"Immunotherapy response assessment in neuro-oncology: A report of the RANO working group","volume":"16","author":"Okada","year":"2015","journal-title":"Lancet Oncol."},{"issue":"17","key":"2024080523460533400_CIT0046","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.22.01579","article-title":"Evaluation of standard response assessment in neuro-oncology, modified response assessment in neuro-oncology, and immunotherapy response assessment in neuro-oncology in newly diagnosed and recurrent glioblastoma","volume":"41","author":"Youssef","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"2024080523460533400_CIT0047","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"issue":"Jan","key":"2024080523460533400_CIT0048","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.radonc.2019.07.013","article-title":"Pseudoprogression after radiation therapies for low grade glioma in children and adults: A systematic review and meta-analysis","volume":"142","author":"Lu","year":"2020","journal-title":"Radiother Oncol."},{"issue":"5","key":"2024080523460533400_CIT0049","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/neuonc\/noz042","article-title":"Increased risk of pseudoprogression among pediatric low-grade glioma patients treated with proton versus photon radiotherapy","volume":"21","author":"Ludmir","year":"2019","journal-title":"Neuro Oncol"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/26\/8\/1357\/58739909\/noae074.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/26\/8\/1357\/58739909\/noae074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T19:48:00Z","timestamp":1722887280000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/26\/8\/1357\/7671506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":49,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,5,14]]},"published-print":{"date-parts":[[2024,8,5]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noae074","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,5,14]]}}}